Price Alert

C4 Therapeutics Inc. (CCCC)

NASDAQ: CCCC · Real-Time Price · USD

2.72

0.05 (1.87%)

At close: Sep 05, 2025, 3:59 PM

2.74

0.74%

After-hours: Sep 05, 2025, 07:06 PM EDT

1.87% (1D)

Bid	2.64
Market Cap	193.58M
Revenue (ttm)	34.24M
Net Income (ttm)	-111.58M
EPS (ttm)	-1.66
PE Ratio (ttm)	-1.64
Forward PE	n/a
Analyst	Buy

Ask	2.86
Volume	1,401,700
Avg. Volume (20D)	1,523,453
Open	2.71
Previous Close	2.67
Day's Range	2.64 - 2.85
52-Week Range	1.08 - 7.22
Beta	2.98

About CCCC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CCCC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CCCC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

C4 Therapeutics Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 weeks ago

+31.63%

C4 Therapeutics shares are trading higher after th... Unlock content with Pro Subscription

News

4 weeks ago · zacks.com

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.26 per share a year ago.

2 months ago · seekingalpha.com

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerabil...